Home » CRISPR gene-editing technology to treat cancer and blood disorders has matured since it was first implemented

CRISPR gene-editing technology to treat cancer and blood disorders has matured since it was first implemented

by Nikos Kokkorakis

A very interesting news article was published on the website of the journal Nature which comments on the whole course of CRISPR genetic modification technology. In this article, all the therapeutic successes of the technology regarding blood disorders, such as β-thalassemia and Fanconi anaemia, which increase the risk of developing cancer, are highlighted. Nevertheless, the potential risks arising from the co-adjuvant application and action of chemotherapy in order to rid the affected body of the unedited blood stem cells, so that the subsequent transplantation of the genetically modified stem cells can succeed, were also highlighted. Regarding this, techniques have already been developed, such as the “prime”editing that overcomes these scopes. Taken together, these approaches and others could be crucial to making gene-editing therapies for blood disorders safer and more affordable.

 

Source

 

Source image

You may also like